EP0823910A1 - Esters of carbapenems - Google Patents

Esters of carbapenems

Info

Publication number
EP0823910A1
EP0823910A1 EP96919678A EP96919678A EP0823910A1 EP 0823910 A1 EP0823910 A1 EP 0823910A1 EP 96919678 A EP96919678 A EP 96919678A EP 96919678 A EP96919678 A EP 96919678A EP 0823910 A1 EP0823910 A1 EP 0823910A1
Authority
EP
European Patent Office
Prior art keywords
compound
methyl
ethyl
formula
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96919678A
Other languages
German (de)
French (fr)
Inventor
George Smithkline Beecham Pharmaceuticals Burton
Stephen SmithKline Beecham Pharmaceuticals MOSS
A. SmithKline Beecham Pharmaceuticals EGLINGTON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9508956.1A external-priority patent/GB9508956D0/en
Priority claimed from GBGB9508955.3A external-priority patent/GB9508955D0/en
Priority claimed from GBGB9508957.9A external-priority patent/GB9508957D0/en
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of EP0823910A1 publication Critical patent/EP0823910A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
    • C07D477/10—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D477/12—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6
    • C07D477/14—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
    • C07D477/02—Preparation
    • C07D477/06—Preparation from compounds already containing the ring or condensed ring systems, e.g. by dehydrogenation of the ring, by introduction, elimination or modification of substituents
    • C07D477/08—Modification of a carboxyl group directly attached in position 2, e.g. esterification
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • This invention relates to novel antibacterial compounds, processes for their preparation, pharmaceutical and veterinary compositions comprising them, and their use in antibacterial therapy.
  • Carbapenems such as imipenem, the compound of formula (A):
  • Stability towards DHP-1 may also be imparted by chemical modification of the carbapenem nucleus, for instance by incorporating a l ⁇ -methyl substitutent, as in the compound meropenem, the compound of formula (B):
  • An alternative approach to imparting improved stability to DHP-1 utilises 2- carbon substituted carbapenems, for instance, 2-aryl, 2-heteroaryl and 2- heteroaromatic carbapenems (US 4543 257, US 4260 627, US 4962 101, US 4 978 659, EP 0 14493, EP 0414489, EP 0 010 316 and EP 0 030 032 Merck & Co) and 2-(substituted)methyl carbapenems (Schmidt et al, J.Antibiotics, 41, 1988, 780).
  • 2-aryl, 2-heteroaryl and 2- heteroaromatic carbapenems US 4543 257, US 4260 627, US 4962 101, US 4 978 659, EP 0 14493, EP 0414489, EP 0 010 316 and EP 0 030 032 Merck & Co
  • 2-(substituted)methyl carbapenems Schot al, J.Antibiotics, 41, 1988
  • UK Patent 1 593 524, Merck & Co. discloses a number of 5-membered heteroaromatic carbapenem derivatives including diazolyl and tetrazolyl compounds. However, in the case of the pyrazolyl derivatives the heterocyclic compound is attached to the carbapenem nucleus through the C-4 position.
  • R a is hydrogen or methyl and R D is hydrogen or lower alkyl
  • R a and R D are selected from hydrogen, lower alkyl, aminocarbonyl, lower alkoxy, cyano, nitro and lower alkoxycarbonyl (EP 0430037, Banyu Pharmaceutical Co.).
  • R a is hydrogen or methyl
  • R D is hydrogen or lower alkyl
  • R a and R D are selected from hydrogen, lower alkyl, aminocarbonyl, lower alkoxy, cyano, nitro and lower alkoxycarbonyl
  • R ⁇ is hydrogen, optionally substituted (C ⁇ _6)alkyl or optionally substituted aryl;
  • RP is hydrogen, optionally substituted or optionally substituted aryl; or R ⁇ and RP together form an optionally substituted 5 or 6 membered heterocyclic ring with or without additional heteroatoms;
  • R c is (Ci _6)alkyl which is unsubstituted or substituted by fluoro, a hydroxy group which is optionally protected by a readily removable hydroxy protecting group, or by an amino group which is optionally protected by a readily removable amino protecting group;
  • Rd is hydrogen or methyl
  • R is selected from the group consisting of isobutyryloxymethyl, (5-methyl-2- oxo-l,3-dioxolen-4-yl)methyl, and benzoyloxymethyl.
  • Particular compounds in accordance with the present invention are: isobutyryloxymethyl (5R, 6S)-2-[l-ethyl-5-methylpyrazol-3-yl]-6-[(lR)-l- hydroxyethyl]-carbapen-2-em-3-carboxylate,
  • each carbapenem compound of the present invention is intended for use in pharmaceutical compositions, it will be understood that it is provided in substantially pure form, for example at least 50% pure, more suitably at least 75% pure and preferably at least 95% pure (% are on a wt/wt basis). Impure preparations of the compound may be used for preparing the more pure forms used in the pharmaceutical compositions. Preferably, whenever possible, each compound of the present invention is obtained in crystalline form
  • solvent of crystallisation may be present in the crystalline product.
  • This invention includes within its scope such solvates.
  • the compounds of this invention may be crystallised or recrystallised from solvents containing water. In such cases water of hydration may be present in the crystalline product.
  • This invention includes within its scope stoichiometric hydrates.
  • the carbapenem antibiotic compounds according to the invention may be formulated for administration in any convenient way for use in human or veterinary medicine, according to techniques and procedures per se known in the art with reference to other antibiotics, and the invention therefore includes within its scope a pharmaceutical composition comprising an antibiotic compound according to the present invention together with a pharmaceutically acceptable carrier or excipient.
  • the compositions may be formulated for administration by any suitable route, such as oral, parenteral or topical application, although the oral route is particularly preferred.
  • the compositions may be in the form of tablets, capsules, powders, granules, lozenges, creams or liquid preparations, such as oral or sterile parenteral solutions or suspensions.
  • Tablets and capsules for oral administration may be in unit dose presentation form and may contain conventional excipients such as binding agents, for example, syrup acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrollidone; fillers, for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tabletting lubricants, for example magnesium stearate, talc, polyethylene glycol or silica; disintegrants, for example potato starch; or acceptable wetting agents such as sodium lauryl sulphate.
  • the tablets may be coated according to methods well known in normal pharmaceutical practice.
  • Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use.
  • Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, methyl cellulose, glucose syrup, gelatin, hydroxyethyl cellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats; emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example almond oil, oily esters, glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl /7-hydroxybenzoate or sorbic acid; and, if desired conventional flavouring or colouring agents.
  • suspending agents for example sorbitol, methyl cellulose, glucose syrup, gelatin, hydroxyethyl cellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats
  • emulsifying agents for example lecithin, sorbitan monooleate, or aca
  • fluid unit dosage forms are prepared utilising the compound and a sterile vehicle, water being preferred.
  • the compound depending on the vehicle and concentration used, can be either suspended or dissolved in the vehicle.
  • the compound can be dissolved in water for injection and filter sterilised before filling into a suitable vial or ampoule and sealing.
  • agents such as local anaesthetic, preservative and buffering agents can be ' dissolved in the vehicle.
  • the composition can be frozen after filling into the vial and the water removed under vacuum. The dry lyophilised powder is then sealed in the vial and an accompanying vial of water for injection may be supplied to reconstitute the liquid prior to use.
  • Parenteral suspensions are prepared in substantially the same manner except that the compound is suspended in the vehicle instead of being dissolved and sterilisation cannot be accomplished by filtration.
  • the compound can be sterilised by exposure to ethylene oxide before suspending in the sterile vehicle.
  • a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.
  • the composition may contain from 0.1% to 99.5% by weight, preferably from 10-60% by weight, of the active material, depending on the method of administration. Where the compositions comprise dosage units, each unit will preferably contain from 50-500 mg of the active ingredient.
  • the dosage as employed for adult human treatment will preferably range from 100 mg to 12 g per day for an average adult patient (body weight 70 kg), for instance 1500 mg per day, depending on the route and frequency of administration. Such dosages correspond to approximately 1.5 to 170 mg kg per day. Suitably the dosage is from 1 to 6g per day.
  • the daily dosage is suitably given by administering a compound of the invention several times in a 24-hour period. Typically, 250 mg is administered 4 times a day although, in practice, the dosage and frequency of administration which will be most suitable for an individual patient will vary with the age, weight and response of the patients, and there will be occasions when the physician will choose a higher or lower dosage and a different frequency of administration. Such dosage regimens are within the scope of this invention.
  • the present invention also provides for the use of a compound of formula (I) for the manufacture of a medicament for treating bacterial infection.
  • the compounds of the present invention of formula (I) are active against a broad range of Gram-positive and Gram-negative bacteria, and may be used to treat a wide range of bacterial infections including those in immunocompromised patients.
  • the compounds of the invention are of value in the treatment of skin, soft tissue, respiratory tract and urinary tract infections in humans and may-also be used to treat mastitis in cattle.
  • a particular advantage of the antibacterially active compounds of this invention is their stability to ⁇ -lactamase enzymes and they are therefore effective against ⁇ -lactamase producing organisms.
  • the present invention further provides a process for the preparation of a compound of formula (I) wherein R is isobutyryloxymethyl or benzoyloxymethyl, which process comprises treating a corresponding compound of formula (I), wherein R is an alkali metal cation, with a compound of formula XCH2OCOCHMe2 or XCH2OCOC6H5, wherein X is a leaving group such as halogen, more particularly bromine or iodine.
  • the reaction is typically carried out at between 0 and 60 C, for example at ambient temperature, under an inert, for example argon, atmosphere, in a suitable organic solvent , for example, N-methylpyrrolidin-2-one.
  • the present invention further provides a process for the preparation of a compound of formula (I) wherein R is (5-methyl-2-oxo-l,3-dioxolen-4-yl)methyl, which process comprises treating a corresponding compound of formula (I), wherein R is an alkali metal cation, with a ula:
  • X is a leaving group such as halogen, more particularly bromine or iodine.
  • the reaction is typically carried out at between 0 and 60 C, for example at ambient temperature, in a suitable organic solvent , for example, N-methylpyrrolidin- 2-one, and in the presence of an acid-binding agent, such as 2,6-lutidine.
  • suitable acid-binding agents include pyridine and diisopropylethylamine.
  • suitable solvents include N, N'-dimethylformamide and N, N'-dimethylacetamide.
  • ICH2 ⁇ COCHMe2 iodomethyl isobutyrate
  • iodomethyl benzoate can be prepared from the corresponding chlorides via the Finkelstein reaction, which is well known to those skilled in the art.
  • Chloromethyl isobutyrate and chloromethyl benzoate can be prepared by esterifying isobutyric acid or benzoic acid respectively with chloromethyl chlorosulphate (Binderup et al., Synthetic Commun., 14(9), 857-864 (1984)).
  • the following Examples illustrate the present invention further:
  • N-Ethylhydrazine oxalate (12 g) in glacial acetic acid (100 ml) was cooled in an ice- bath and treated with ethyl 2,4-dioxovalerate (11.24 ml). After addition was complete the mixture was stirred at room temperature; after ca. 45 min the mixture was warmed to dissolve insoluble ethylhydrazine oxalate. The mixture was stirred for a further 2 h and then poured into water( ca. 300 ml) / ethyl acetate (ca. 700 ml) and solid K2CO3 was carefully added, with stirring, untiLthe pH was neutral.
  • Ethyl l-ethyl-5-methylpyrazole-3-carboxylate (10.93 g) in ethanol (70 ml) was treated with KOH (3.69 g), followed by water (30 ml), and the mixture was stirred and heated under reflux for 6 h.
  • the ethanol was removed using a rotary evaporator and ethyl acetate/water were added.
  • the pH of the mixture was adjusted to 3.0 and the layers were separated.
  • the aqueous layer was re-extracted with ethyl acetate.
  • the combined ethyl acetate layers were extracted with excess aqueous NaHCO3.
  • the NaHCO3 extract was poured into excess acid, and the pH was then adjusted to 3, and NaCl was added to the solution.
  • the resultant acid chloride was redissolved in dry dichloromethane and then treated with N,0- dimethylhydroxylamine hydrochloride (3.61 g). The mixture was cooled in an ice- bath and treated with pyridine (6.0 ml), the mixture was then allowed to stir at room temperature for 1.5 h and then diluted with ether (100 ml) and washed with brine. The organic layer was then dried (MgSO4) and evaporated to leave an oil.
  • the mixture was diluted with ethyl acetate , washed with water, then with brine, and dried (MgSO4). After removal of the ethyl acetate the crude product was chromatographed on silica gel, eluting with ethyl acetate/hexane mixtures to give the phosphorane, which was used in the next stage.
  • the phosphorane prepared above was taken up in 1,4-dioxan (60 ml) and treated with 5M HCl (20 ml). After 1 h the mixture was carefully treated with ca. 40 ml saturated aqueous NaHCO3, followed by solid NaHCO3 until the pH was slightly alkaline. Saturated brine was added and the mixture was extracted twice with ethyl acetate. The combined extracts were dried (M SO4) and evaporated.
  • the residual solid was dried under a stream of argon, and then in a desiccator.
  • the solid was then taken up in water containing sodium chloride and chromatographed on DIAION HP20SS resin, eluting with water, followed by water/THF mixtures; 1%, 2%, and 3%,THF.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

A compound of formula (I), wherein R is selected from the group consisting of isobutyryloxymethyl, (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl, and benzoyloxymethyl, is useful in the treatment of bacterial infections.

Description

ESTERS OF CARBAPENEMS
This invention relates to novel antibacterial compounds, processes for their preparation, pharmaceutical and veterinary compositions comprising them, and their use in antibacterial therapy.
Carbapenems such as imipenem, the compound of formula (A):
(A) have a potent, broad spectrum of antibacterial activity (see US 3 950 357 and US 4 194047; Merck and Co). Such carbapenems however tend to be vulnerable to hydrolysis by the enzyme renal dehydropeptidase-1 (DHP-1) and this limits their use in chemotherapy. In the case of imipenem, this problem may be overcome by the co- administration of an inhibitor of DHP-1.
Stability towards DHP-1 may also be imparted by chemical modification of the carbapenem nucleus, for instance by incorporating a lβ-methyl substitutent, as in the compound meropenem, the compound of formula (B):
(B) (see Shih D.H. et al., Heterocycles, 1984, 21, 29 and Sunagawa M. et al., J. Antibiotics, 1990, 43, 519). More recently, this has been extended to a lβ- aminoalkyl substituent (see EP 0433759, Bristol-Meyers Squibb).
An alternative approach to imparting improved stability to DHP-1 utilises 2- carbon substituted carbapenems, for instance, 2-aryl, 2-heteroaryl and 2- heteroaromatic carbapenems (US 4543 257, US 4260 627, US 4962 101, US 4 978 659, EP 0 14493, EP 0414489, EP 0 010 316 and EP 0 030 032 Merck & Co) and 2-(substituted)methyl carbapenems (Schmidt et al, J.Antibiotics, 41, 1988, 780).
UK Patent 1 593 524, Merck & Co. discloses a number of 5-membered heteroaromatic carbapenem derivatives including diazolyl and tetrazolyl compounds. However, in the case of the pyrazolyl derivatives the heterocyclic compound is attached to the carbapenem nucleus through the C-4 position. Other structural modifications introduced at position-2 include a substituted vinyl group -C(Ra)=CHRD in which, for instance, Ra is hydrogen or methyl and RD is hydrogen or lower alkyl (EP 0330 108; Fujisawa) or Ra and RD are selected from hydrogen, lower alkyl, aminocarbonyl, lower alkoxy, cyano, nitro and lower alkoxycarbonyl (EP 0430037, Banyu Pharmaceutical Co.). In the absence of a lβ- methyl substituent, such a modification does not however appear to impart DHP-1 stability.
International Patent Application No. PCT/GB94/02347 describes compounds of the general formula (C):
(C) in which R is:
wherein
Rα is hydrogen, optionally substituted (Cι_6)alkyl or optionally substituted aryl;
RP is hydrogen, optionally substituted or optionally substituted aryl; or Rα and RP together form an optionally substituted 5 or 6 membered heterocyclic ring with or without additional heteroatoms;
Rc is (Ci _6)alkyl which is unsubstituted or substituted by fluoro, a hydroxy group which is optionally protected by a readily removable hydroxy protecting group, or by an amino group which is optionally protected by a readily removable amino protecting group;
Rd is hydrogen or methyl; and
-CO2Re is carboxy or a carboxylate anion or the group Re is a readily removable carboxy protecting group. According to the present invention, there is provided the compound of formula (I):
(I) wherein R is selected from the group consisting of isobutyryloxymethyl, (5-methyl-2- oxo-l,3-dioxolen-4-yl)methyl, and benzoyloxymethyl.
Particular compounds in accordance with the present invention are: isobutyryloxymethyl (5R, 6S)-2-[l-ethyl-5-methylpyrazol-3-yl]-6-[(lR)-l- hydroxyethyl]-carbapen-2-em-3-carboxylate,
(5-methyl-2-oxo-l,3-dioxolen-4-yl)methyl (5R, 6S)-2-[l-ethyl-5- methylpyrazol-3-yl]-6-[(lR)-l-hydroxyethyl]-carbapen-2-em-3-carboxylate, and benzoyloxymethyl (5R, 6S)-2-[l-ethyl-5-methylpyrazol-3-yl]-6-[(lR)-l- hydroxyethyl]-carbapen-2-em-3-carboxylate. Since each carbapenem compound of the present invention is intended for use in pharmaceutical compositions, it will be understood that it is provided in substantially pure form, for example at least 50% pure, more suitably at least 75% pure and preferably at least 95% pure (% are on a wt/wt basis). Impure preparations of the compound may be used for preparing the more pure forms used in the pharmaceutical compositions. Preferably, whenever possible, each compound of the present invention is obtained in crystalline form
When each compound of this invention is allowed to crystallise or is recrystallised from organic solvents, solvent of crystallisation may be present in the crystalline product. This invention includes within its scope such solvates. Similarly, the compounds of this invention may be crystallised or recrystallised from solvents containing water. In such cases water of hydration may be present in the crystalline product. This invention includes within its scope stoichiometric hydrates.
The carbapenem antibiotic compounds according to the invention may be formulated for administration in any convenient way for use in human or veterinary medicine, according to techniques and procedures per se known in the art with reference to other antibiotics, and the invention therefore includes within its scope a pharmaceutical composition comprising an antibiotic compound according to the present invention together with a pharmaceutically acceptable carrier or excipient. The compositions may be formulated for administration by any suitable route, such as oral, parenteral or topical application, although the oral route is particularly preferred. The compositions may be in the form of tablets, capsules, powders, granules, lozenges, creams or liquid preparations, such as oral or sterile parenteral solutions or suspensions. Tablets and capsules for oral administration may be in unit dose presentation form and may contain conventional excipients such as binding agents, for example, syrup acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrollidone; fillers, for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tabletting lubricants, for example magnesium stearate, talc, polyethylene glycol or silica; disintegrants, for example potato starch; or acceptable wetting agents such as sodium lauryl sulphate. The tablets may be coated according to methods well known in normal pharmaceutical practice. Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, methyl cellulose, glucose syrup, gelatin, hydroxyethyl cellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats; emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example almond oil, oily esters, glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl /7-hydroxybenzoate or sorbic acid; and, if desired conventional flavouring or colouring agents. Suppositories will contain conventional suppository base, eg cocoa-butter or other glyceride.
For parenteral administration, fluid unit dosage forms are prepared utilising the compound and a sterile vehicle, water being preferred. The compound, depending on the vehicle and concentration used, can be either suspended or dissolved in the vehicle. In preparing solutions the compound can be dissolved in water for injection and filter sterilised before filling into a suitable vial or ampoule and sealing. Advantageously, agents such as local anaesthetic, preservative and buffering agents can be 'dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum. The dry lyophilised powder is then sealed in the vial and an accompanying vial of water for injection may be supplied to reconstitute the liquid prior to use. Parenteral suspensions are prepared in substantially the same manner except that the compound is suspended in the vehicle instead of being dissolved and sterilisation cannot be accomplished by filtration. The compound can be sterilised by exposure to ethylene oxide before suspending in the sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound. The composition may contain from 0.1% to 99.5% by weight, preferably from 10-60% by weight, of the active material, depending on the method of administration. Where the compositions comprise dosage units, each unit will preferably contain from 50-500 mg of the active ingredient. The dosage as employed for adult human treatment will preferably range from 100 mg to 12 g per day for an average adult patient (body weight 70 kg), for instance 1500 mg per day, depending on the route and frequency of administration. Such dosages correspond to approximately 1.5 to 170 mg kg per day. Suitably the dosage is from 1 to 6g per day.
The daily dosage is suitably given by administering a compound of the invention several times in a 24-hour period. Typically, 250 mg is administered 4 times a day although, in practice, the dosage and frequency of administration which will be most suitable for an individual patient will vary with the age, weight and response of the patients, and there will be occasions when the physician will choose a higher or lower dosage and a different frequency of administration. Such dosage regimens are within the scope of this invention.
No toxicological effects are indicated when any compound of the invention is administered in the above mentioned dosage range.
The present invention also includes a method of treating bacterial infections in humans and animals which method comprises administering a therapeutically effective amount of an antibiotic compound of the present invention of the formula
(I).
In a further aspect, the present invention also provides for the use of a compound of formula (I) for the manufacture of a medicament for treating bacterial infection. The compounds of the present invention of formula (I) are active against a broad range of Gram-positive and Gram-negative bacteria, and may be used to treat a wide range of bacterial infections including those in immunocompromised patients.
Amongst many other uses, the compounds of the invention are of value in the treatment of skin, soft tissue, respiratory tract and urinary tract infections in humans and may-also be used to treat mastitis in cattle.
A particular advantage of the antibacterially active compounds of this invention is their stability to β-lactamase enzymes and they are therefore effective against β-lactamase producing organisms.
The present invention further provides a process for the preparation of a compound of formula (I) wherein R is isobutyryloxymethyl or benzoyloxymethyl, which process comprises treating a corresponding compound of formula (I), wherein R is an alkali metal cation, with a compound of formula XCH2OCOCHMe2 or XCH2OCOC6H5, wherein X is a leaving group such as halogen, more particularly bromine or iodine. The reaction is typically carried out at between 0 and 60 C, for example at ambient temperature, under an inert, for example argon, atmosphere, in a suitable organic solvent , for example, N-methylpyrrolidin-2-one. Other suitable solvent systems include N, N'-dimethylformamide and N, N'-dimethylacetamide. The present invention further provides a process for the preparation of a compound of formula (I) wherein R is (5-methyl-2-oxo-l,3-dioxolen-4-yl)methyl, which process comprises treating a corresponding compound of formula (I), wherein R is an alkali metal cation, with a ula:
wherein X is a leaving group such as halogen, more particularly bromine or iodine. The reaction is typically carried out at between 0 and 60 C, for example at ambient temperature, in a suitable organic solvent , for example, N-methylpyrrolidin- 2-one, and in the presence of an acid-binding agent, such as 2,6-lutidine. Other suitable acid-binding agents include pyridine and diisopropylethylamine. Other suitable solvents include N, N'-dimethylformamide and N, N'-dimethylacetamide. Compounds of formula (I) wherein R is an alkali metal cation,, such as sodiumy are described in International Patent Application No. PCT/GB94/02347, and hereinbelow in Preparation 1.
The compound of formula ICH2θCOCHMe2 (iodomethyl isobutyrate) and iodomethyl benzoate can be prepared from the corresponding chlorides via the Finkelstein reaction, which is well known to those skilled in the art.
Chloromethyl isobutyrate and chloromethyl benzoate can be prepared by esterifying isobutyric acid or benzoic acid respectively with chloromethyl chlorosulphate (Binderup et al., Synthetic Commun., 14(9), 857-864 (1984)). The following Examples illustrate the present invention further:
General Instructions - Solutions were dried using anhydrous magnesium sulphate and solvents were removed by evaporation under reduced pressure using a rotary evaporator. Column chromatography on silica gel used Merck silica gel 60, particle size <0.063mm. Example 1
fcobutyryloxymethyI-(5R, 65)-2-(l-ethyl-5-methylpyrazoI-3-yI)-6-[(lR)-l- hydroxyethyI]carbapen-2-em-3-carboxylate
The product from Preparation 1 (200 mg, 0.61 mmol) was dissolved in N- methylpyrrolidin-2-one (2 ml). A solution of isobutyryloxymethyl iodide (360 mg, 1.6 mmol) in N-methylpyrrolidin-2-one (0.5 ml) was added to this solution at room temperature under argon and after 0.5 h the reaction mixture was diluted with ethyl acetate (15 ml) and the solution was washed with water (3 x 15 ml), 5% sodium thiosulfate solution (15 ml) and then saturated brine (15 ml). The organic extract was dried (Na2SO4) and concentrated to an oil which was purified by chromatography on silica gel eluting with an acetone/toluene gradient mixture to yield a pale yellow solid which was recrystallised from diethyl ether to afford the title compound as pale yellow microneedles (100 mg, 40%), m.p. 107-8°C; (Found: M+, 405.1899. C20H27N3O6 requires M 405.1900); vmax(CHCl3) 3458, 3019, 1772 and 1734 cπr !; δH(CDCl3) 1.19 (6H, d, 77.1 Hz), 1.36 (3H, d, 76.1 Hz), 1.40 (3H, t, 77.2 Hz), 1.76 (IH, d, 74.9 Hz), 2.29 (3H, s), 2.62 (IH, septet, 77.1 Hz), 3.18 (IH, dd, 72.7, 6.5 Hz), 3.30 (IH, dd, 79.0, 18.8 Hz), 3.64 (IH, dd, 79.8, 18.8 Hz), 4.08 (2H, q, 77.2 Hz), 4.16-4.30 (2H, m), 5.92 (IH, d, 75.6 Hz), 5.98 (IH, d, 75.6 Hz) and 7.02 (IH, s).
Example 2
(5-Methyl-2-oxo-l,3-dioxolen-4-yl)methyl (5R,6S)-6-[(Λ)-l-hydroxyethyI]-2-(l- ethyI-5-methyl-pyrazoI-3-yl)carbapen-2-em-3-carboxylate
Sodium (5R,65)-6-[(R)-l-hydroxyethyl]-2-(l-ethyl-5-methylpyrazol-3-yl)carbapen-2- em-3-carboxylate (300 mg) in N-methylpyrrolidinone (4 ml) was treated with 2,6- lutidine (ca. 30 mg) followed by 4-bromomethyl-5-methyl-l,3-dioxol-2-one (290 mg) [F.*Sakamoto, S. D eda and G. Tsukamoto, Chem. Pharm Bull. 32, (6), 2241 - 2248 (1984)] in tetrahydrofuran (1 ml). The mixture was stirred for 1.25 h. Ethyl acetate and water were added and the layers separated. The aqueous layer was re- extracted with ethyl acetate and the combined ethyl acetate layers were washed with water, followed by saturated brine solution, and then dried (MgSO4). The filtered solution was stored in a refrigerator overnight and then evaporated and chromatographed on silica gel (230 - 400 mesh ASTM) (2.5 x 12 cm column), loading in CH2CI2 / hexane, and eluting with ethyl acetate. Fractions containing the product were combined and evaporated to give a colourless solid which was recrystallised from acetone to give crystals of (5-methyl-2-oxo-l,3-dioxolen-4- yl)methyl (5R,6S)-6-[(Λ)-l-hydroxyethyl]-2-(l-ethyl-5-methylpyrazol-3-yl)carbapen-
2-em-3-carboxylate, m. p. 148 - 151°C; υmax(CH2Cl2) 3605, 2975, 1823, 1776,
1737 (sh), 1721, 1598, 1546, 1314, 1231, and 1182 cm"1; λmax(EtOH/nm 325 (ε
/dπ^moHcnr1 14,654), 260.5 (ε/dπ^moHcπr1 3404); 0XCDCI3) 1.36 (3H, d, 7 6.2 Hz), 1.40 (3H, t, 7 ca. 7.3 Hz), 1.76 (lH,d, 74.9 Hz), 2.21 (3H, s), 2.30 (3H, s),
3.19 (IH, dd, 72.7 & 6.5 Hz), 3.31 (IH, dd, 79.0 & 18.7 Hz), 3.61 (IH, dd, 79.9 &
18.7 Hz), 4.08 (2H, q, 77.3 Hz), 4.16 - 4.30 (2H, m), 5.00 & 5.07 (2H, ABq, J 13.9
Hz), 6.88 (IH, s) ppm; Found (El ms) m/z 417 (M+).
Example 3
Benzoyloxymethyl (5R,6S)-2-(l-ethyl-5-methylpyrazol-3-yl)-6-[(lR)-l- hydroxyethyl]carbapen-2-em-3-carboxylate
The product from Preparation 1 (200 mg, 0.61 mmol) was dissolved in N- methylpyrrolidin-2-one (2 ml). A solution of benzoyloxymethyl iodide (336 mg, 1.28 mmol) in N-methylpyrrolidin-2-one (0.5 ml) was added to this solution at room temperature under argon and after 0.5 h the reaction mixture was diluted with ethyl acetate (15 ml) and the solution was washed with water (3 x 15 ml), 5% sodium thiosulfate solution (15 ml) and then saturated brine (15 ml). The organic extract was dried (Na2SO4) and concentrated to an oil which was purified by chromatography on silica gel eluting with an acetone/toluene gradient mixture to yield a pale yellow solid which was recrystallised from acetone/diethyl ether to afford the title compound as a white solid (143 mg, 53%), m.p. 131-4°C; (Found: M+, 439.1743. C22H25N O6 requires M 439.1743); υmaχ(CHCl3) 3021, 1740, 1602, 1452 and 1440 cm"1 ; δ H(CDC 3) 1-3 (6H, m), 1.70 (IH, d, 74.9 Hz), 2.25 (3H,s), 3.19 (IH, dd, 72.4, 6.3 Hz), 3.30 (IH, dd, 78:8, 18.8 Hz), 3.64 (IH, dd, 710.1, 18.8 Hz), 4.07 (2H, q, 77.2 Hz), 4.18-4.31 (2H, m), 6.20 (2H, s), 7.42-7.48 (2H, m), 7.56-7.61 (IH, m), and 8.10 (2H, d, 77.1 Hz) ppm.
Preparation 1
Sodium (5R,6S)-6-[(R)-l-hydroxyethyl]-2-(l-ethyI-5-methylpyrazol-3- yl)carbapen-2-em-3-carboxylate
(a) Ethyl l-ethyl-5-methylpyrazoIe-3-carboxyIate
N-Ethylhydrazine oxalate (12 g) in glacial acetic acid (100 ml) was cooled in an ice- bath and treated with ethyl 2,4-dioxovalerate (11.24 ml). After addition was complete the mixture was stirred at room temperature; after ca. 45 min the mixture was warmed to dissolve insoluble ethylhydrazine oxalate. The mixture was stirred for a further 2 h and then poured into water( ca. 300 ml) / ethyl acetate (ca. 700 ml) and solid K2CO3 was carefully added, with stirring, untiLthe pH was neutral. After separation the aqueous layer was re-extracted with ethyl acetate. The combined ethyl acetate extracts were dried (MgSO4), and the solvents removed to leave an oil. Chromatography on silica gel, loading in CH2θ2/hexane and eluting with a gradient elution of ethyl acetate/hexane mixtures (from 2:8 to 1:1) gave ethyl l-ethyl-5- methylpyrazole-3-carboxylate as an oil (13.2 g); υmax (CH2CI2) 1717, 1446, 1389, and 1219 cm*1; 0 CDCI3) 1.38 (3H, t, 77.2 Hz), 1.42 (3H, t, 77.3 Hz), 2.30 (3H, s), 4.17 (2H, q, 77.3 Hz), 4.38 (2H, q, 77.1 Hz), 6.55 (IH, s); (Found m/z 182.1055. C9H14N2O2 requires m/z 182.1055).
(b) l-Ethyl-5-methylpyrazole-3-carboxylic acid
Ethyl l-ethyl-5-methylpyrazole-3-carboxylate (10.93 g) in ethanol (70 ml) was treated with KOH (3.69 g), followed by water (30 ml), and the mixture was stirred and heated under reflux for 6 h. The ethanol was removed using a rotary evaporator and ethyl acetate/water were added. The pH of the mixture was adjusted to 3.0 and the layers were separated. The aqueous layer was re-extracted with ethyl acetate. The combined ethyl acetate layers were extracted with excess aqueous NaHCO3. The NaHCO3 extract was poured into excess acid, and the pH was then adjusted to 3, and NaCl was added to the solution. The mixture was then repeatedly extracted with ethyl acetate, and the combined extracts were dried (MgSO4) and evaporated. The residue was triturated" with diethyl ether to give the acid as a solid (5.65 g); υmax (CH2C1 ) 2754, 2598, 1698, 1498, 1464, 1387, and 1233 cm"1; 0XCDCI3) 1.40 (3H, t, 77.3 Hz), 2.32 (3H,s), 4.19 (2H, q, 77.3 Hz), 6.61 (lH,s) ppm; (Found m/z 154.0740. C7H10N2O2 requires m/z 154.0742).
(c)N-Methoxy-N-methyl-l-ethyl-5-methylpyrazoIe-3-carboxamide
l-Ethyl-5-methylpyrazole-3-carboxylic acid (5.25 g) in dry dichloromethane (100 ml) containing N,N-dimethylformamide (0.26 ml) was cooled in an ice-bath and treated with a solution of oxalyl chloride (3.27 ml) in dichloromethane (25 ml), added dropwise. The mixture was stirred in the cold for 25 min, and then allowed to warm to room temperature, when evolution of a gas was observed. After 10 min the solvent was removed by evaporation in vacuo and toluene was added and removed (x 2) to ensure any residual HC1 and oxalyl chloride had been removed. The resultant acid chloride was redissolved in dry dichloromethane and then treated with N,0- dimethylhydroxylamine hydrochloride (3.61 g). The mixture was cooled in an ice- bath and treated with pyridine (6.0 ml), the mixture was then allowed to stir at room temperature for 1.5 h and then diluted with ether (100 ml) and washed with brine. The organic layer was then dried (MgSO4) and evaporated to leave an oil. This was the chromatographed on silica gel, loading in dichloromethane, and eluting with ethyl acetate / hexane mixtures to give, after evaporation of requisite fractions, the hydroxamate (5.2 g) as a solid; υraax(CH2Cl2) 2982, 2937, 1641, 1489, 1445, 1379,and 975 cm' ; δ\CDCl3) 1.43 (3H, t, 77.3 Hz), 2.29 (3H, s), 3.42 (3H, s), 3.76 (3H, s, ), 4.13 (2H, q, 77.3 Hz), 6.49 (IH, s); (Found m/z 197.1164. C9H15N3O requires m/z 197.1164).
(d) 3-Acetyl-l-ethyl-5-methylpyrazole
N-Methoxy-N-methyl-l-ethyl-5-methylpyrazole-3-carboxamide (3.12 g) in dry tetrahydrofuran (60 ml) was cooled in an ice-bath and treated with a 3.0M solution of methylmagnesium bromide in ether (11.08 ml). After stirring for 1.5 h the mixture was poured into a mixture of methanol (100 ml) and 5M aqueous HC1 (10 ml) in an ice-bath. The mixture was then evaporated to lower volume and treated with a mixture of dichloromethane, water and saturated brine. After separation the aqueous layer was re-extracted with dichloromethane. The combined dichloromethane extracts were dried (MgSO4) and evaporated to leave an oil (2.26 g), which solidified on standing; υmax (CH2Cl2) 1680, 1446, 1425, 1380, 1324, 1208, and 945 cm"1; δ (CDCI3) 1.44 (3H, t, 77.3 Hz), 2.30 (3H, s), 2.53 (3H, s), 4.13 (2H, q, 77.3 Hz,), 6.51 (lH,s); (Found: m/z 152.0949. CgH^^O requires m/z 152.090).
(e) (3S,4K)-4-[(l-ethyl-5-methylpyrazol-3-yl)carbonylmethyI]-3-[(R)-l-tert- butyldimethyIsiIyloxyethyl]azetidin-2-one
3-Acetyl-l-ethyl-5-methylpyrazole (3.51 g) in dry tetrahydrofuran (THF) (150 ml) under an argon atmosphere was cooled in an acetone / solid carbon dioxide bath and then treated with a 1M solution of lithium bis(trimethylsilyl)amide (50 ml). The mixture was stirred for 45 minutes and then (3R,4R)-4-acetoxy-3-[(lR)-l-tέ?rt- butyldimethylsilyloxyethyl]azetidinone (6.6 g) was added as a solid under a blanket oi argon. The mixture was stirred in the cold for 3.:>n. saturated aqueous ammonium chloride was then added, followed by ethyl acetate, and the mixture was allowed to warm to room temperature. A little water was added and the layers were separated and the aqueous layer was re-extracted with ethyl acetate. The combined ethyl acetate extracts were washed with saturated brine, dried and evaporated.
Chromatography on silica gel, eluting with ethyl acetate/hexane mixtures gave the title compound (3.65 g), υmax (CH C-2) 3411, 1761, 1678, 1376, 1151, and 838 cnr 1; 0XCDCI3) 0.064 (6H, s), 0.86 (9H, s), 1.20 (3H,d, 76.3 Hz), 1.44 (3H, t, 77.3 Hz), 2.31 (3H, s), 2.89 (IH, dd, 7 1.8 & 4.9 Hz), 3.15 (IH, dd, 7 10.0 & 17.1 Hz), 3.50 (IH, dd, 73.5 & 17.0 Hz), 4.06 - 4.25 (4H, m), 6.11 (IH, s), 6.53 (IH, s). (Found m/z 379.2296. C! 9^3^0381 requires m/z 379.2291).
(f) Allyl (2R and 2S)-2-{(3S,4R)-4-[(l-ethyl-5-methylpyrazol-3- yl)carbonyImethyl]-3-[(R)-l-tert-butyldimethylsilyloxyethyl]-2-oxoazetidinyl}-2- hydroxyacetate.
(3S,4R)-4-[(l-Ethyl-5-methylpyrazol-3-yl)carbonylmethyl]-3-[(/?)-l-tert- butyldimethylsilyloxyethyl]azetidin-2-one (3.6 g) and allyl glyoxylate hydrate (1.66 g) in toluene (100 ml) were heated under reflux in a Dean and Stark apparatus under an atmosphere of argon for 3.5h. T.l.c. of the reaction mixture showed the reaction had almost prceeded to completion, so more allyl glyoxylate hydrate (190 mg) was added and the mixture was heated under reflux for a further 45 min. The mixture was cooled, the toluene was removed to give crude allyl (2R and 2S)-2-{(35,4fi)-4-[(l- ethyl-5-methylpyrazol-3-yl)carbonylmethyl] -3-[(/?)- 1 -tert- butyldimethylsilyloxyethyl]-2-oxoazetidinyl}-2-hydroxyacetate, which was used in the next stage; υmax (CH2C12) 3681, 3518, 1758, 1676, 1448, 1376, 1326, 1209, 1148, 1092, 954, and 836 cm"1; 0XCDCI3) inter alia 0.035 (s), 0.061 (s) (together 6H,), 0.858 (s), 0.865 (s) (together 9H), 1.21 (d, 76.2 Hz), 1.24 (d, 76.2 Hz), (together 3H), 1.44 (3H, t, 77.2 Hz), 2.31 (3H, s), 2.95 - 3.00 (IH, m), 3.25 - 3.64 (2H, m), 6.53 (s), 6.56 (s) ppm.
(g) Allyl 2-{(3S,4R)-4-[(l-ethyl-5-methylpyrazoI-3-yI)carbonylmethyl]-3-[(R)-l- te t-butyldimethyIsilyloxyethyl]-2-oxoazetidinyl}-2-(tri-/ι- butylphosphoranylidene)acetate.
Allyl (2R and 2S)-2-{(35,4R)-4-[(l-ethyl-5-methylpyrazol-3- yl)carbonylmethyl]-3-[(R)-l-t<?rt-butyldimethylsilyloxyethyl]-2-oxoazetidinyl}-2- hydroxyacetate (crude from the above preparation) in dry THF (125 ml) under argon was cooled to -20°C and treated with 2,6-lutidine (1.98 ml), followed by thionyl chloride (1.24 ml). The mixture was stirred at -20°C for 30 minutes, and then allowed to warm to room temperature and filtered, washing the residue with THF (20 ml). The filtrate was evaporated in vacuo, toluene (70ml) was added and removed in vacuo and the residual oil was dried in vacuo. The oil was then taken up in 1,4- dioxan (40 ml) under an argon atmosphere, and treated with tri- z-butylphosphine (3.11 ml). The mixture was stirred for 1 h. 2,6-Lutidine (1.59 ml) was then added and the mixture was stirred for a further 30 minutes. The mixture was diluted with ethyl acetate , washed with water, then with brine, and dried (MgSO4). After removal of the ethyl acetate the crude product was chromatographed on silica gel, eluting with ethyl acetate/hexane mixtures to give the phosphorane, which was used in the next stage.
(h) Allyl 2-{(3S,4R)-4-[(l-ethyI-5-methylpyrazol-3-yl)carbonylmethyl]-3-[(R)-l- hydroxyethyl]-2-oxoazetidinyl}-2-(tri-/z-butylphosphoranylidene)acetate.
The phosphorane prepared above was taken up in 1,4-dioxan (60 ml) and treated with 5M HCl (20 ml). After 1 h the mixture was carefully treated with ca. 40 ml saturated aqueous NaHCO3, followed by solid NaHCO3 until the pH was slightly alkaline. Saturated brine was added and the mixture was extracted twice with ethyl acetate. The combined extracts were dried (M SO4) and evaporated. The residue was chromatographed on silica gel, eluting with ethyl acetate/hexane mixtures to give the hydroxy compound, (2.60 g), υmax (CH2C-2) 3454, 1741, 1667, 1606, 1448, 1403, 1379, 1155, 1087, 953, and 811 cm"1.
(i) Allyl (5R,6S)-6-[(R)-l-hydroxyethyl]-2-(l-ethyl-5-methylpyrazoI-3- yl)carbapen-2-em-3-carboxylate Allyl 2-{(3S,4R)-4-[(l-ethyl-5-methylρyrazol-3-yl)carbonylmethyl]-3-[(R)-l- hydroxyethyl]-2-oxoazetidinyl}-2-(tri-/i-butylphosphoranylidene)acetate (2.6 g), in toluene (120 ml) containing hydroquinone (20 mg) was heated under reflux in an argon atmosphere for 4 h, allowed to stand for 64 h, and then heated under reflux for a further 2 h. The mixture was cooled and then loaded onto a column (4.5 x 12 cm) of silica gel (particle size 0.040 -0.063 mm), eluting with ethyl acetate/hexane mixtures; 1:1; 6:4; 7:3; 8:2; 9:1 (250 ml of each), followed by ethyl acetate. This gave the carbapenem (436 mg); υmax(CH2Cl2) 3604, 2976, 1774, 1716, 1600, 1546,
1311, 1189 cm"1; λmax(EtOH)/nm 321.5 (ε/dmSmol- l 14,856), 0 CDCI3) 1.36 (d, 76.3 Hz), 1.39 (t, 77.3 Hz) (together 5H), 1.80 (lH, d, 75.0 Hz), 2.28
(3H,s), 3.19 (IH, dd 72.7 & 6.7 Hz), 3.28 (IH, dd, 79.0 & 18.6 Hz), 3.60 (IH, dd, 7
9.9 & 18.5 Hz), 4.08 (2H, q, 77.3 Hz), 4.16 - 4.30 (2H, m), 4.68 - 4.90 (2H, m), 5.27
(IH, m, approx d, J ca. 12 Hz), 5.46 (m, approx d, J ca. 17 Hz), 5.93 - 6.08 (IH, m),
7.00 (IH, s) ppm; [Found m/z 345.1693. C18H23N3O4 requires m/z 345.1689].
Q) Sodium (5R,6S)-6-[(R)-l-hydroxyethyI]-2-(l -ethyI-5-methyl-pyrazoI-3- yl)carbapen-2-em-3-carboxylate
Allyl (5R,6S)-6-[(R)-l-hydroxyethyl]-2-(l-ethyl-5-methylpyrazol-3- yl)carbapen-2-em-3-carboxylate (267 mg) in dichloromethane (3ml) and ethyl acetate (3 ml) under argon was treated with sodium 2-ethylhexanoate (183 mg), followed by triphenylphosphine (24 mg), followed by tetrakis(triphenylphosphine)palladium(0) (35 mg) and the mixture was stirred for 45 min. Diethyl ether (100ml) was then added, and after stirring for 90 minutes, the mixture was centrifuged. The residual solid was dried under a stream of argon, and then in a desiccator. The solid was then taken up in water containing sodium chloride and chromatographed on DIAION HP20SS resin, eluting with water, followed by water/THF mixtures; 1%, 2%, and 3%,THF. Fractions were monitored by HPLC, and those containing the product were combined, reduced in volume and freeze-dried to give sodium (5R,6S)-6-[(R)-l- hydroxyethyl]-2-(l-ethyl-5-methylpyrazol-3-yl)carbapen-2-em-3-carboxylate as a solid (168 mg); υmax(KBr) 1761, 1608, 1577, 1381, 1225 cm'l; λmax(H2O)/nm 298 (ε/dm3mol-lcm-l 8,531); δ(D2O) 1.26 (d, J ca. 6 Hz), 1.27 (d, J ca. 1 Hz) (together 5H), 2.23 (3H, s), 3.17 (2H, approx d, J ca. 9 Hz), 3.44 (IH, dd, 72.9 & 6.0 Hz), 4.04 (2H, q, 77.3 Hz), 4.15 - 4.25 (2H, m), 6.41 (IH, s) ppm.

Claims

Claims
A compound of formula (I):
wherein R is selected from the group consisting of isobutyryloxymethyl, (5-methyl-2- oxo-l,3-dioxolen-4-yl)methyl, and benzoyloxymethyl.
2. Isobutyryloxymethyl (5R, 6S)-2-[l-ethyl-5-methylpyrazol-3-yl]-6-[(lR)-l- hydroxyethyl]-carbapen-2-em-3-carboxylate.
3. (5-Methyl-2-oxo-l,3-dioxolen-4-yl)methyl (5R, 6S)-2-[l-ethyl-5- methylpyrazol-3-yl]-6-[(lR)-l-hydroxyethyl]-carbapen-2-em-3-carboxylate.
4. Benzoyloxymethyl (5R, 6S)-2-[l-ethyl-5-methylpyrazol-3-yl]-6-[(lR)-l- hydroxyethyl]-carbapen-2-em-3-carboxylate.
5. A pharmaceutical composition comprising a compound according to any one of the preceding claims together with a pharmaceutically acceptable carrier or excipient
6. A method of treating bacterial infections in humans and animals which method comprises administering a therapeutically effective amount of a compound according to any one claims 1 to 4.
7. Use of a compound according to any one of claims 1 to 4 for the manufacture of a medicament for treating bacterial infection.
8. A process for the preparation of a compound of formula (I) as defined in claim 1 wherein R is isobutyryloxymethyl or benzoyloxymethyl, which process comprises treating a corresponding compound of formula (I), wherein R is an alkali metal cation, with a compound of formula XCH2θCOCHMβ2 or XCH2OCOC6H5, wherein X is a leaving group.
9. A process for the preparation of a compound of formula (I) as defined in claim 1 wherein R is (5-methyl-2-oxo-l,3-dioxolen-4-yl)methyl, which process comprises treating a corresponding compound of formula (I), wherein R is an alkali metal cation, with a compound of formula:
wherein X is a leaving group.
EP96919678A 1995-05-03 1996-05-02 Esters of carbapenems Withdrawn EP0823910A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB9508957 1995-05-03
GBGB9508956.1A GB9508956D0 (en) 1995-05-03 1995-05-03 Novel compounds
GBGB9508955.3A GB9508955D0 (en) 1995-05-03 1995-05-03 Novel compounds
GBGB9508957.9A GB9508957D0 (en) 1995-05-03 1995-05-03 Novel compounds
GB9508956 1995-05-03
GB9508955 1995-05-03
PCT/EP1996/001880 WO1996034868A1 (en) 1995-05-03 1996-05-02 Esters of carbapenems

Publications (1)

Publication Number Publication Date
EP0823910A1 true EP0823910A1 (en) 1998-02-18

Family

ID=27267696

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96919678A Withdrawn EP0823910A1 (en) 1995-05-03 1996-05-02 Esters of carbapenems

Country Status (22)

Country Link
EP (1) EP0823910A1 (en)
JP (1) JPH11504910A (en)
KR (1) KR19990008355A (en)
CN (1) CN1185783A (en)
AR (1) AR005416A1 (en)
AU (1) AU5813996A (en)
BG (1) BG102014A (en)
BR (1) BR9608313A (en)
CA (1) CA2217990A1 (en)
CZ (1) CZ347597A3 (en)
EA (1) EA199700293A1 (en)
HU (1) HUP9801066A3 (en)
IL (1) IL118092A0 (en)
MA (1) MA23853A1 (en)
MX (1) MX9708421A (en)
NO (1) NO974994L (en)
OA (1) OA10632A (en)
PE (1) PE50697A1 (en)
PL (1) PL323141A1 (en)
SK (1) SK146497A3 (en)
TR (1) TR199701286T1 (en)
WO (1) WO1996034868A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2902659A1 (en) 2006-06-23 2007-12-28 Pierre Fabre Medicament Sa DHA ESTER AND ITS USE IN THE TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASES
WO2013157583A1 (en) * 2012-04-18 2013-10-24 大日本住友製薬株式会社 Novel carbapenem compound

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1593524A (en) * 1976-11-19 1981-07-15 Merck & Co Inc 1-carba-2-penem-3-carboxylic acids
CA1212105A (en) * 1980-04-30 1986-09-30 Shoji Ikeda Ampicillin esters and production thereof
WO1995005380A1 (en) * 1993-08-18 1995-02-23 Sankyo Company, Limited Crystalline carbapenem derivatives
AP9600800A0 (en) * 1993-10-29 1996-04-30 Smithkline Beecham Plc 2-(Pyrazol-3-yl) carbapenem derivatives.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9634868A1 *

Also Published As

Publication number Publication date
PL323141A1 (en) 1998-03-16
OA10632A (en) 2002-09-16
CZ347597A3 (en) 1998-08-12
CA2217990A1 (en) 1996-11-07
KR19990008355A (en) 1999-01-25
AU5813996A (en) 1996-11-21
SK146497A3 (en) 1998-05-06
NO974994D0 (en) 1997-10-30
BG102014A (en) 1998-11-30
MX9708421A (en) 1998-02-28
IL118092A0 (en) 1996-09-12
JPH11504910A (en) 1999-05-11
HUP9801066A3 (en) 1999-01-28
TR199701286T1 (en) 1998-02-21
PE50697A1 (en) 1997-12-18
BR9608313A (en) 1999-01-26
WO1996034868A1 (en) 1996-11-07
EA199700293A1 (en) 1998-06-25
CN1185783A (en) 1998-06-24
AR005416A1 (en) 1999-06-23
NO974994L (en) 1997-10-30
MA23853A1 (en) 1996-12-31
HUP9801066A2 (en) 1998-08-28

Similar Documents

Publication Publication Date Title
JPH0853453A (en) 2-(1-(1,3-thiazolin-2-yl)azetidin-3-yl)thiocarbapenem compound
US6458780B1 (en) Carbapenem derivatives
JP3703146B2 (en) 2- (Pyrazol-3-yl) carbapenem derivatives
WO1996034868A1 (en) Esters of carbapenems
EP0823911A1 (en) Esters of carbapenems
MXPA97008422A (en) Carbapene steres
US5384317A (en) Bridged biphenyl carbapenem compounds, compositions containing such compounds and methods of use
MXPA97008421A (en) Carbapene steres
JPH0798821B2 (en) 2- (9-fluorenonyl) -carbapenem
US5606051A (en) 2-(pyrazol-3-yl)carbapenem derivatives
WO1994017065A1 (en) 2-phenanthridinyl carbapenem antibacterial agents
US5276149A (en) 2-(N-imidazoliumphenyl)-carbapenems
JPH06192273A (en) Carbapenem-3-carboxylic ester derivative
US7045619B2 (en) 2-(pyrazol-3-yl)carbapenem derivatives
US5372993A (en) Bridged carbapenem compounds, compositions containing such compounds and methods of use
PT99285B (en) METHOD FOR THE PREPARATION OF DIETHYACETAL-SUBSTITUTED CARBENIC ACID ANTIBIOTICS IN CARBON 3 ATOM AND OF PHARMACEUTICAL COMPOSITIONS THAT CONTAINS THEM
IE921546A1 (en) Chemical compounds
EP1019405A1 (en) Beta-methylcarbapenem derivatives, process for the preparation thereof and pharmaceutical composition comprising same
JPH09249668A (en) Carbapenem compound, its production and medicine
JPH1045758A (en) Carbapenem compound, its production and agent

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19971107

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: SI PAYMENT 971107

17Q First examination report despatched

Effective date: 19990702

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19991115

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1009126

Country of ref document: HK